FDA approves Sparsentan for proteinuria reduction in IgAN Dr. Kamal Kant Kohli7 Sept 2024 5:00 AM ISTThe US Food and Drug Administration has granted full approval to sparsentan (Filspari) for reduction of proteinuria in adults with IgAN at risk of...
Sparsentan fails to arrest deterioration of eGFR among patients with focal segmental glomerulosclerosis Dr Kartikeya Kohli5 Nov 2023 6:00 PM ISTFocal segmental glomerulosclerosis (FSGS) is a rare and challenging kidney disorder that can lead to significant health consequences, including kidney...
